Stay updated with breaking news from கீந் ஆம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RNA-Binding Proteins Identified as New Class of Drug Target for Cancers, Including Triple Negative Breast Tumors genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
New approach to triple-negative breast cancer targets tumor-driving RNA proteins fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Potential drug target for difficult-to-treat breast cancer: RNA-binding proteins eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
ABC News Turn on desktop notifications for breaking stories about interest? OffOn Malala Yousafzai and more nominate those who are making history in our world. • 309 min read ABC News Photo Illustration Asian American and Pacific Islander Heritage Month celebrates the contributions of one of the fastest-growing groups of people living in the United States. Asian Americans and Pacific Islanders contain multitudes. They are a global community with a homegrown and unique perspective on America. Their diversity expands continents and demographics. The hopes and dreams of the AAPI community are America at its finest, and its people and traditions are those that are tightly stitched into the fabric of the nation. The American dream is alive and well within the AAPI community, and we ve gathered so many of those dreams here throughout this inspiring list of individuals. ....
DLA Piper advises Locanabio in its US$100 million Series B financing News provided by Share this article Share this article NEW YORK, Dec. 15, 2020 /PRNewswire/ DLA Piper represented Locanabio, an RNA-targeting gene therapy company focused on developing life-changing therapies for patients with severe neurodegenerative, neuromuscular and retinal diseases, in its recent US$100 million Series B financing led by Vida Ventures. The round also included participation from new investors RA Capital Management, Invus, Acuta Capital Partners and an investment fund associated with SVB Leerink, as well as prior Locanabio investors ARCH Venture Partners, Temasek, Lightstone Ventures, UCB Ventures and GV. The financing will advance Locanabio s portfolio of RNA-targeted gene therapies and expand the technology platform to pursue a broad range of therapeutic indications. Locanabio is currently developing therapies to treat multiple genetic diseases with no approved the ....